162 related articles for article (PubMed ID: 11045792)
1. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
3. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer.
Dhingra K
J Cell Biochem Suppl; 1995; 23():19-24. PubMed ID: 8747374
[TBL] [Abstract][Full Text] [Related]
4. Effect of tamoxifen on mammographic density.
Chow CK; Venzon D; Jones EC; Premkumar A; O'Shaughnessy J; Zujewski J
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):917-21. PubMed ID: 11008909
[TBL] [Abstract][Full Text] [Related]
5. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
Stearns V; Coop A; Singh B; Gallagher A; Yamauchi H; Lieberman R; Pennanen M; Trock B; Hayes DF; Ellis MJ
Clin Cancer Res; 2004 Nov; 10(22):7583-91. PubMed ID: 15569989
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of breast cancer.
Osborne MP
Surg Clin North Am; 1999 Oct; 79(5):1207-21. PubMed ID: 10572559
[TBL] [Abstract][Full Text] [Related]
8. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
Mohsin SK; Allred DC; Osborne CK; Cruz A; Otto P; Chew H; Clark GM; Elledge RM
Breast Cancer Res Treat; 2005 Dec; 94(3):205-11. PubMed ID: 16267611
[TBL] [Abstract][Full Text] [Related]
9. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
10. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
[TBL] [Abstract][Full Text] [Related]
11. Surrogate response biomarkers in prevention research: do they point the way or lead us astray?
Fabian CJ
J Clin Oncol; 2009 Aug; 27(23):3734-6. PubMed ID: 19597020
[No Abstract] [Full Text] [Related]
12. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M
J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer.
O'Shaughnessy JA
JAMA; 1996 May; 275(17):1349-53. PubMed ID: 8614122
[No Abstract] [Full Text] [Related]
15. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
Ozanne EM; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2043-52. PubMed ID: 15598759
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma-in-situ.
Wickerham DL
J Clin Oncol; 2001 Sep; 19(18 Suppl):98S-100S. PubMed ID: 11560982
[No Abstract] [Full Text] [Related]
19. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
Brewster AM; Christo DK; Lai H; Helzlsouer K
Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen for breast cancer among hysterectomised women.
Veronesi U; Maisonneuve P; Sacchini V; Rotmensz N; Boyle P;
Lancet; 2002 Mar; 359(9312):1122-4. PubMed ID: 11943263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
